Literature DB >> 22741039

Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.

Gregory K Friedman1, Marilyn C Haas, Virginia M Kelly, James M Markert, George Yancey Gillespie, Kevin A Cassady.   

Abstract

Hypoxia plays a critical role in the tumor microenvironment of high-grade gliomas by promoting the glioma stem cell (GSC)-like phenotype, which displays resistance to standard therapies. We tested three glioblastoma multiforme xenograft lines (xenolines) against γ(1)34.5-deleted recombinant oncolytic herpes simplex virus (oHSV) C101 under 1% (hypoxia) and 20.8% (normoxia) oxygen tension for effects on oHSV infectivity, replication, and cytotoxicity in all tumor cells and CD133(+) GSCs. Expression levels of CD133, a putative GSC marker, and CD111 (nectin-1), an adhesion molecule that is the most efficient method for HSV entry, increased significantly under hypoxia in all three xenolines. Despite increased CD111 expression under hypoxic conditions, oHSV infectivity, cytotoxicity and viral recovery were not improved or were diminished in all three xenolines under hypoxia. In contrast, wild-type HSV-1 equally infected xenoline cells in normoxia and hypoxia, suggesting that the 34.5 mutation plays a role in the decreased C101 infectivity in hypoxia. Importantly, CD133(+) cells were not more resistant to oHSV than CD133(-) tumor cells regardless of oxygen tension. Furthermore, CD133 expression decreased as viral dose increased in two of the xenolines suggesting that up-regulation of CD133 in hypoxia was not the cause of reduced viral efficacy. Our findings that oHSV infectivity and cytotoxicity were diminished under hypoxia in several GBM xenolines likely have important implications for clinical applications of oHSV therapies, especially considering the vital role of hypoxia in the microenvironment of GBM tumors.

Entities:  

Year:  2012        PMID: 22741039      PMCID: PMC3384274          DOI: 10.1593/tlo.12115

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  46 in total

1.  Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Authors:  Caterina Giannini; Jann N Sarkaria; Atsushi Saito; Joon H Uhm; Evanthia Galanis; Brett L Carlson; Mark A Schroeder; C David James
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

Review 2.  Impact of tumor microenvironment on oncolytic viral therapy.

Authors:  Jeffrey Wojton; Balveen Kaur
Journal:  Cytokine Growth Factor Rev       Date:  2010 Apr-Jun       Impact factor: 7.638

3.  A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry.

Authors:  D Shukla; J Liu; P Blaiklock; N W Shworak; X Bai; J D Esko; G H Cohen; R J Eisenberg; R D Rosenberg; P G Spear
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

4.  Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen.

Authors:  L Studer; M Csete; S H Lee; N Kabbani; J Walikonis; B Wold; R McKay
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

5.  Hypoxia is important in the biology and aggression of human glial brain tumors.

Authors:  Sydney M Evans; Kevin D Judy; Isolde Dunphy; W Timothy Jenkins; Wei-Ting Hwang; Peter T Nelson; Robert A Lustig; Kevin Jenkins; Deirdre P Magarelli; Stephen M Hahn; Ruth A Collins; M Sean Grady; Cameron J Koch
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

6.  The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.

Authors:  John M Heddleston; Zhizhong Li; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell Cycle       Date:  2009-10-03       Impact factor: 4.534

7.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Authors:  Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

8.  The herpes simplex virus receptor nectin-1 is down-regulated after trans-interaction with glycoprotein D.

Authors:  Katie M Stiles; Richard S B Milne; Gary H Cohen; Roselyn J Eisenberg; Claude Krummenacher
Journal:  Virology       Date:  2008-02-20       Impact factor: 3.616

Review 9.  Autophagy and viral neurovirulence.

Authors:  Anthony Orvedahl; Beth Levine
Journal:  Cell Microbiol       Date:  2008-05-22       Impact factor: 3.715

10.  Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.

Authors:  Gregory K Friedman; Catherine P Langford; Jennifer M Coleman; Kevin A Cassady; Jacqueline N Parker; James M Markert; G Yancey Gillespie
Journal:  J Neurooncol       Date:  2009-06-12       Impact factor: 4.130

View more
  20 in total

1.  Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.

Authors:  J Hughes; P Wang; G Alusi; H Shi; Y Chu; J Wang; V Bhakta; I McNeish; A McCart; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2015-04-16       Impact factor: 5.250

2.  Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.

Authors:  Gregory K Friedman; Blake P Moore; Li Nan; Virginia M Kelly; Tina Etminan; Catherine P Langford; Hui Xu; Xiaosi Han; James M Markert; Elizabeth A Beierle; G Yancey Gillespie
Journal:  Neuro Oncol       Date:  2015-07-16       Impact factor: 12.300

3.  Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance.

Authors:  Dayana B Rivadeneira; Kristin DePeaux; Yiyang Wang; Aditi Kulkarni; Tracy Tabib; Ashley V Menk; Padmavathi Sampath; Robert Lafyatis; Robert L Ferris; Saumendra N Sarkar; Stephen H Thorne; Greg M Delgoffe
Journal:  Immunity       Date:  2019-08-27       Impact factor: 31.745

4.  Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.

Authors:  J D Jackson; A M McMorris; J C Roth; J M Coleman; R J Whitley; G Y Gillespie; S L Carroll; J M Markert; K A Cassady
Journal:  Gene Ther       Date:  2014-08-14       Impact factor: 5.250

5.  Herpes Simplex Virus 1 ICP34.5 Alters Mitochondrial Dynamics in Neurons.

Authors:  Richard Manivanh; Jesse Mehrbach; Audra J Charron; Andrew Grassetti; Stacey Cerón; Sean A Taylor; Jorge Rubén Cabrera; Scott Gerber; David A Leib
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

6.  γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.

Authors:  G K Friedman; L Nan; M C Haas; V M Kelly; B P Moore; C P Langford; H Xu; X Han; E A Beierle; J M Markert; K A Cassady; G Y Gillespie
Journal:  Gene Ther       Date:  2014-11-27       Impact factor: 5.250

7.  Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children.

Authors:  Gregory K Friedman; Elizabeth A Beierle; George Yancey Gillespie; James M Markert; Alicia M Waters; Chun-Yu Chen; Nicholas L Denton; Kellie B Haworth; Brian Hutzen; Jennifer L Leddon; Keri A Streby; Pin-Yi Wang; Timothy P Cripe
Journal:  Mol Ther Oncolytics       Date:  2015-09-16       Impact factor: 7.200

8.  Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.

Authors:  Timothy P Cripe; Chun-Yu Chen; Nicholas L Denton; Kellie B Haworth; Brian Hutzen; Jennifer L Leddon; Keri A Streby; Pin-Yi Wang; James M Markert; Alicia M Waters; George Yancey Gillespie; Elizabeth A Beierle; Gregory K Friedman
Journal:  Mol Ther Oncolytics       Date:  2015-09-16       Impact factor: 7.200

9.  HIF-1α downregulation and apoptosis in hypoxic prostate tumor cells infected with oncolytic mammalian orthoreovirus.

Authors:  Pooja Gupta-Saraf; Cathy L Miller
Journal:  Oncotarget       Date:  2014-01-30

10.  Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy.

Authors:  Gregory K Friedman; Joel Raborn; Virginia M Kelly; Kevin A Cassady; James M Markert; G Yancey Gillespie
Journal:  Front Oncol       Date:  2013-02-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.